Skip to content

Study · Animal study (in vivo) · mouse · 2023

2 results

Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.

Born E, Lipskaia L, Breau M, Houssaini A, Beaulieu D, Marcos E, Pierre R, Do Cruzeiro M, Lefevre M, Derumeaux G, Bulavin DV, Delcroix M and 7 more

Show all authors

Quarck R, Reen V, Gil J, Bernard D, Flaman JM, Adnot S, Abid S

Circulation14 Dec 2022Cited by 136 (Europe PMC)

PMID36515093 (opens in a new tab)DOI10.1161/circulationaha.122.058794 (opens in a new tab)PepBankPUB-36515093
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In SM22-5-HTT+ mice, FOXO4‑DRI (like ABT263) was associated with pulmonary hemodynamic alterations compared with relevant controls.

    In plain wordsIn mice prone to lung blood pressure problems, FOXO4‑DRI was linked to changes in lung blood flow pressure compared with controls.

    Peptide
    FOXO4-DRI
    Outcome
    Direction not reportedPulmonary hemodynamic alterations
    Study

    mousen: not reported in source

    SM22-5-HTT+ mice (pulmonary hypertension model)
    Comparator
    Relevant controls
    Outcome group
    Cardiovascular events · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pulmonary hemodynamic alterations and lung P-EC loss occurred in older p16LUC/LUC mice, wild-type mice exposed to Sugen or hypoxia+Sugen, and SM22-5-HTT+ mice given either ABT263 or FOXO4-DRI, compared with relevant controls.
    1 context sentence
    Summary · context
    We investigated pulmonary hypertension in mice exposed to normoxia, chronic hypoxia, or hypoxia+Sugen, mice overexpressing the serotonin transporter (SM22-5-HTT+), and rats given monocrotaline.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In SM22-5-HTT+ mice, FOXO4‑DRI (like ABT263) was associated with loss of lung pulmonary endothelial cells compared with relevant controls.

    In plain wordsIn mice prone to lung blood pressure problems, FOXO4‑DRI was linked to loss of lung blood vessel lining cells compared with controls.

    Peptide
    FOXO4-DRI
    Outcome
    DecreaseLung pulmonary endothelial cell number
    Study

    mousen: not reported in source

    SM22-5-HTT+ mice (pulmonary hypertension model)
    Comparator
    Relevant controls
    Outcome group
    Cell viability and death · Respiratory
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pulmonary hemodynamic alterations and lung P-EC loss occurred in older p16LUC/LUC mice, wild-type mice exposed to Sugen or hypoxia+Sugen, and SM22-5-HTT+ mice given either ABT263 or FOXO4-DRI, compared with relevant controls.
    1 context sentence
    Summary · context
    We investigated pulmonary hypertension in mice exposed to normoxia, chronic hypoxia, or hypoxia+Sugen, mice overexpressing the serotonin transporter (SM22-5-HTT+), and rats given monocrotaline.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.